Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
August 23, 2024
RegMed Investors’ (RMi) pre-open: suffering conflicting views
August 22, 2024
RegMed Investors (RMi) Closing Bell: a daily cell and gene therapy sector wobble
August 21, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy enjoyed the closing dinner
August 19, 2024
RegMed Investors (RMi) Closing Bell: forget Godot, Waiting for Jerome
August 16, 2024
RegMed Investors (RMi) Closing Bell: follow the bouncing sector share pricing
August 14, 2024
RegMed Investors (RMi) Closing Bell: incoming, algorithmic barrage explodes our portfolios
August 9, 2024
RegMed Investors (RMi) Closing Bell: No sector recovery, I knew Friday would be a bust
August 8, 2024
RegMed Investors (RMi) Closing Bell: sector in the green with jobless claims surprise
August 7, 2024
RegMed Investors (RMi) Closing Bell: As I anticipated, NO follow through session
August 6, 2024
RegMed Investors (RMi) Closing Bell: sector returns to an upside
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors